Mingshan Cheng

Jackson Laboratory — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

11h-index795citations118works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Research and Treatments(62), RNA modifications and cancer(39), Epigenetics and DNA Methylation(38), CAR-T cell therapy research(24), Cancer Cells and Metastasis(14)

Publications118 total

Mapping the genetic landscape establishing a tumor immune microenvironment favorable for anti-PD-1 response
Cell Reports·2025· 3 citedOpen Access
Mapping the genetic landscape establishing a tumor immune microenvironment favorable for anti-PD-1 response in mice and humans
2024Open Access
Abstract 111: Establishing orthotopic renal cell carcinoma xenograft in PBMC-humanized immunodeficient NSG-MHC I/II double knock-out mice
Cancer Research·2024
Abstract 6718: Evaluating toxicity and efficacy of bispecific EGFRXCD3 T cell engager in solid tumor-bearing humanized animal model
Cancer Research·2024
Development of a Novel Solid Tumor-Bearing Humanized Animal Model for Simultaneously Evaluating the Toxicity and Efficacy of Bispecific T Cell Engager
Blood·2023
Simultaneous evaluation of treatment efficacy and toxicity for bispecific T‐cell engager therapeutics in a humanized mouse model
The FASEB Journal·2023· 14 citedOpen Access
A novel tumor-bearing humanized mouse model for evaluating the efficacy and predictive safety of bispecific T cell engager
The Journal of Immunology·2023· 1 citedOpen Access
Abstract LB349: The use of PBMC humanized mice to test the efficacy and safety of antibody and cell-based cancer immunotherapeutics
Cancer Research·2023
Abstract 5189: Comparisons of Rituximab and CD19xCD3 BiTE antitumor response across multiple humanized NSG strains engrafted with human hematopoietic stem cells
Cancer Research·2023
Abstract 6354: A new tumor-bearing humanized mouse model to evaluate the efficacy of bispecific T cell engager and monoclonal checkpoint antibodies
Cancer Research·2023· 1 cited
Data from Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions
2023Open Access
Figure S1 from Modeling of Patient-Derived Xenografts in Colorectal Cancer
2023Open Access
Supplementary Data from Modeling of Patient-Derived Xenografts in Colorectal Cancer
2023Open Access
Figure S1 from Modeling of Patient-Derived Xenografts in Colorectal Cancer
2023Open Access
Data from Modeling of Patient-Derived Xenografts in Colorectal Cancer
2023Open Access
Supplementary Figures 1-8 from Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions
2023Open Access
Data from Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions
2023Open Access
Data from Modeling of Patient-Derived Xenografts in Colorectal Cancer
2023Open Access
Supplementary Figures 1-8 from Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions
2023Open Access
Supplementary Data from Modeling of Patient-Derived Xenografts in Colorectal Cancer
2023Open Access
page 1 of 6Next →

Frequent Co-authors

James Keck(44), Li‐Chin Yao(16), Edison T. Liu(14), Jonathan W. Riess(14), Carol J. Bult(14), Susan Airhart(13), Leonard D. Shultz(13), David R. Gandara(13), Danying Cai(12), Philip C. Mack(12), Michael A. Brehm(11), Regina Gandour‐Edwards(11), Rebekah A. Tsai(11), Xing Yi Woo(10), Anuj Srivastava(10), Joel H. Graber(10), Brian J. Sanderson(10), Michael W. Lloyd(10), Mandy Chen(10), Sergii Domanskyi(10)